Drug Profile
IMGN 388
Alternative Names: CNTO 365; CNTO 95-DM4; IMGN-388Latest Information Update: 14 Feb 2024
Price :
$50
*
At a glance
- Originator Centocor
- Developer ImmunoGen
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Maytansinoids; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Mitosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 12 Feb 2024 ImmunoGen has been acquired by AbbVie
- 22 May 2012 ImmunoGen completes enrolment in its phase I trial for Solid tumours in USA (NCT00721669)
- 29 Nov 2011 Discontinued - Phase-I for Solid tumours in USA (IV)